The main difference between the two agents is that PDE5i’s effects are dependent on NO synthesis, while guanylate cyclase stimulators are characterized by the possibility of directly stimulating sGC via a different binding site, independently of NO, whose bioavailability is reduced in PAH patients [86]. Here, SGCB is linked to pulmonary arterial hypertension.